Kymera Therapeutics, Inc. 8-K

What Happened Kymera Therapeutics, Inc. (KYMR) filed an 8-K reporting the results of its Annual Meeting of Shareholders held on June 24, 2026. Shareholders elected four Class III directors — Bruce Booth, D.Phil.; Nello Mainolfi, Ph.D.; John Maraganore, Ph.D.; and Elena Ridloff, CFA — each for a three‑year term ending in 2029. Shareholders also approved, on a non‑binding advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as Kymera’s independent registered public accounting firm for the 2026 fiscal year.

Key Details

• Director election votes:
  • Bruce Booth: For 71,962,459; Withheld 5,430,527; Broker non‑votes 1,707,176
  • Nello Mainolfi: For 73,411,316; Withheld 3,981,670; Broker non‑votes 1,707,176
  • John Maraganore: For 72,501,958; Withheld 4,891,028; Broker non‑votes 1,707,176
  • Elena Ridloff: For 72,453,404; Withheld 4,939,582; Broker non‑votes 1,707,176
• Advisory vote on executive compensation: For 74,903,687; Against 2,462,732; Abstain 26,567; Broker non‑votes 1,707,176.
• Ratification of independent auditor (Ernst & Young LLP): For 79,043,801; Against 38,128; Abstain 18,233; no broker non‑votes.
• The proxy statement describing these proposals was filed with the SEC on April 29, 2026; no other matters were voted on.

Why It Matters These results confirm the company’s board composition and governance direction through 2029 and show strong shareholder support for management’s pay practices (non‑binding advisory) and for retaining Ernst & Young as auditor. For investors, re‑election of directors and ratification of the auditor reduce near‑term governance uncertainty; the advisory vote outcome signals continued investor acceptance of executive compensation but is not binding.